Late-Breaking Clinical Trial Results Announced at VIVA 2026

VIVA 2026 presented results from multiple vascular-device and treatment studies, with several reporting improved outcomes in peripheral artery disease and pulmonary embolism. In the 300-patient SELUTION4SFA trial, the sirolimus-eluting balloon achieved 12-month efficacy of 78.6% versus 65.2% for angioplasty and safety of 92.8% versus 84.2%; the 597-patient SirPAD analysis found target-lesion revascularization of 17.0% versus 27.1% at one year. Other reported findings included 69% versus 50% complete wound healing at four weeks with oxygen therapy and a 0.9% major-adverse-event rate in the 107-subject TRUST thrombectomy study; results are study-specific and largely clinical, so broader market implications are limited.

Analysis

The investable signal is a possible shift in PAD intervention mix, not a near-term revenue inflection. Randomized sirolimus-balloon evidence could make plain balloon angioplasty harder to defend where operators and payers prioritize fewer repeat procedures; over 6–18 months, that favors differentiated drug-delivery platforms and pressures lower-cost POBA use. It does not yet establish share gains versus established drug-coated balloons or drug-eluting stents: the SELUTION4SFA cohort is modest, lesion lengths differed between arms, and several other favorable readouts are single-arm, subgroup, or interim analyses. Conference data need peer-reviewed scrutiny and confirmation of regulatory status, reimbursement, and purchasing adoption before translating into estimates.

The more speculative second-order signal is adjunctive care: montelukast and transdermal oxygen could reduce repeat procedures or wound-care burden, but small studies are insufficient to underwrite drug or device demand. The two-year IVL data also illustrate a key counterpoint—improved lesion treatment does not eliminate the high mortality and limb-event burden of advanced CLTI, especially in complex patients.

For Garmin (GRMN), the wearable analysis is a small feasibility cohort showing correlation with clinic-based walking capacity, not evidence that Garmin devices improve outcomes or are becoming standard of care. Any commercial read-through is remote and immaterial absent clinical adoption or a disclosed health-system partnership. No mapped medtech issuer is supplied, so attributing trial results to a public ticker would be speculative. Near-term market impact should be limited; adoption, guideline changes, and reimbursement are 1–3 year catalysts.

Key Decisions for Investors

• No immediate position from this conference release. Treat the sirolimus-balloon readouts as a watch item, not proof of a category-wide earnings upgrade.
• Over the next 1–3 months, verify publication and full methods for SELUTION4SFA and SirPAD, device regulatory status, and whether clinicians or payers indicate substitution away from POBA or existing drug-coated balloons. Reassess only if adoption evidence emerges.
• Keep GRMN market-weight; do not capitalize the small STORM-PE wearable cohort as a material revenue catalyst. Revisit only if Garmin discloses clinical-channel partnerships, recurring health-monitoring revenue, or broader trial deployment.
• Falsifiers for the PAD adoption thesis: weaker durability in longer follow-up, safety or regulatory concerns, no reimbursement/procurement traction, or subsequent comparative evidence showing no advantage over established drug-coated balloons or stents.